Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Common nonsense mutations in RAD52.

D W Bell1, D C Wahrer, D H Kang

  • 1Center for Cancer Risk Analysis, Massachusetts General Hospital Cancer Center, and Harvard Medical School, Charlestown 02129, USA.

Cancer Research
|August 27, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13AR.

ESMO open·2025
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer.

ESMO open·2024
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer.

ESMO open·2023
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Diving pattern, lung volumes, and alveolar gas of the Korean diving woman (ama)

Journal of applied physiology (Bethesda, Md. : 1985)·2019
Same author

Lung volumes and ventilatory responses to high CO2 and low O2 in the ama

Journal of applied physiology (Bethesda, Md. : 1985)·2019
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

Researchers investigated RAD51, RAD52, and RAD54 genes for mutations in breast cancer. They found no evidence that these DNA repair genes are mutated in human breast cancer, suggesting they are not a primary target in this disease.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cancer Research

Background:

  • Homologous recombination is crucial for repairing double-strand DNA breaks.
  • RAD51, RAD52, and RAD54 proteins are key players in this DNA repair pathway.
  • BRCA1 and BRCA2 breast cancer susceptibility genes interact with RAD proteins, suggesting a functional link.

Purpose of the Study:

  • To investigate RAD51, RAD52, and RAD54 genes for germ-line and somatic mutations in breast cancer.
  • To determine if these DNA repair genes are mutated in early-onset breast cancer and cell lines.
  • To assess the potential role of RAD gene mutations in breast cancer development.

Main Methods:

  • Screening of RAD51, RAD52, and RAD54 genes for germ-line mutations in 100 early-onset breast cancer cases.

Related Experiment Videos

  • Analysis of RAD genes for somatic mutations in 15 human breast cancer cell lines.
  • Comparison of mutation frequencies with a healthy control population.

    • Main Results:

    • Two heterozygous premature stop codon mutations (Ser346ter, Tyr415ter) were found in RAD52 germ-line alleles in 5% of breast cancer cases and 8% of controls.
    • A rare germ-line missense mutation was identified in RAD54; no variants were found in RAD51.
    • No somatic mutations in RAD51, RAD52, or RAD54 were detected in breast cancer cell lines.

    Conclusions:

    • RAD51, RAD52, and RAD54 are not significantly mutated in human breast cancer, despite their role in DNA repair and association with BRCA genes.
    • The identified RAD52 mutations are common in the general population and do not increase breast cancer risk.
    • These findings suggest that RAD51, RAD52, and RAD54 are unlikely to be primary targets for mutations in breast cancer.